A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...
Ideaya Bullish on Registration Plans for Darovasertib, Xalkori Combo After Positive Melanoma Readout
The company is hoping to seek accelerated approval in first-line HLA-A*A2:01-negative metastatic uveal melanoma based on data ...
Morning Overview on MSN
IDEAYA-Servier eye cancer drug hits trial goal, clearing path to FDA filing
A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...
EM, biochemical, and cell-based assays to examine how Gβγ interacts with and potentiates PLCβ3. The authors present evidence for multiple Gβγ interaction surfaces and argue that Gβγ primarily enhances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results